TGFB1 and plasma cell myeloma: In the studies presented here, we have shown for the first time that the bone anabolic 1D11 (anti‐TGFβ antibody), when administered in combination with the antiresorptive Zol, provided a therapeutic strategy for both the prevention and, more importantly, in the treatment of myeloma‐induced bone disease.